98 related articles for article (PubMed ID: 36615725)
1. The FIB-4 Index Predicts the Development of Liver-Related Events, Extrahepatic Cancers, and Coronary Vascular Disease in Patients with NAFLD.
Kamada Y; Munekage K; Nakahara T; Fujii H; Sawai Y; Doi Y; Hyogo H; Sumida Y; Imai Y; Miyoshi E; Ono M;
Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615725
[TBL] [Abstract][Full Text] [Related]
2. Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study.
Huang DQ; Tran S; Barnett S; Zou B; Yeo YH; Cheung R; Nguyen MH
Hepatol Int; 2024 Apr; 18(2):540-549. PubMed ID: 38079023
[TBL] [Abstract][Full Text] [Related]
3. The greater impact of PNPLA3 polymorphism on liver-related events in Japanese non-alcoholic fatty liver disease patients: A multicentre cohort study.
Seko Y; Yamaguchi K; Shima T; Iwaki M; Takahashi H; Kawanaka M; Tanaka S; Mitsumoto Y; Yoneda M; Nakajima A; Fjellström O; Blau JE; Carlsson B; Okanoue T; Itoh Y
Liver Int; 2023 Oct; 43(10):2210-2219. PubMed ID: 37470077
[TBL] [Abstract][Full Text] [Related]
4. Predicting liver-related events in NAFLD: A predictive model.
Calzadilla-Bertot L; Jeffrey GP; Wang Z; Huang Y; Garas G; Wallace M; de Boer B; George J; Eslam M; Phu A; Ampuero J; Lucena Valera A; Romero-Gómez M; Aller de la Fuente R; Adams LA
Hepatology; 2023 Oct; 78(4):1240-1251. PubMed ID: 36994693
[TBL] [Abstract][Full Text] [Related]
5. Decline in serum albumin concentration is a predictor of serious events in nonalcoholic fatty liver disease.
Kawaguchi K; Sakai Y; Terashima T; Shimode T; Seki A; Orita N; Takeshita Y; Shimakami T; Takatori H; Arai K; Kitamura K; Yamashita T; Yamashita T; Takamura M; Mizukoshi E; Takamura T; Honda M; Wada T; Kaneko S
Medicine (Baltimore); 2021 Aug; 100(31):e26835. PubMed ID: 34397849
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease.
Cholankeril G; Kramer JR; Chu J; Yu X; Balakrishnan M; Li L; El-Serag HB; Kanwal F
J Hepatol; 2023 Mar; 78(3):493-500. PubMed ID: 36402450
[TBL] [Abstract][Full Text] [Related]
7. Agile 3+ and Agile 4, noninvasive tests for liver fibrosis, are excellent formulae to predict liver-related events in nonalcoholic fatty liver disease.
Miura K; Hayashi H; Kamada Y; Fujii H; Takahashi H; Oeda S; Iwaki M; Kawaguchi T; Tomita E; Yoneda M; Tokushige A; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T;
Hepatol Res; 2023 Oct; 53(10):978-988. PubMed ID: 37353881
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease.
Thomas JA; Kendall BJ; El-Serag HB; Thrift AP; Macdonald GA
Lancet Gastroenterol Hepatol; 2024 Feb; 9(2):159-169. PubMed ID: 38215780
[TBL] [Abstract][Full Text] [Related]
9. Identification of clinical phenotypes associated with poor prognosis in patients with nonalcoholic fatty liver disease via unsupervised machine learning.
Ito T; Morooka H; Takahashi H; Fujii H; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Ishigami M; Kamada Y; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T;
J Gastroenterol Hepatol; 2023 Oct; 38(10):1832-1839. PubMed ID: 37596843
[TBL] [Abstract][Full Text] [Related]
10. Patients with type 2 diabetes and elevated fibrosis-4 are under-referred to hepatology and have unrecognized hepatic decompensation.
Dunn W; Song X; Koestler D; Grdinovac K; Al-Hihi E; Chen J; Taylor R; Wilson J; Weinman SA
J Gastroenterol Hepatol; 2022 Sep; 37(9):1815-1821. PubMed ID: 35613944
[TBL] [Abstract][Full Text] [Related]
11. Poor accuracy and sustainability of the first-step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population.
De Vincentis A; Tavaglione F; Namba S; Kanai M; Okada Y; Kamatani Y; Maurotti S; Pedone C; Antonelli Incalzi R; Valenti L; Romeo S; Vespasiani-Gentilucci U
Aliment Pharmacol Ther; 2024 Jun; 59(11):1402-1412. PubMed ID: 38497224
[TBL] [Abstract][Full Text] [Related]
12. FIB‑4 index and NAFLD fibrosis score are useful indicators for screening high‑risk groups of non‑viral hepatocellular carcinoma.
Imai K; Takai K; Unome S; Miwa T; Hanai T; Suetsugu A; Shimizu M
Mol Clin Oncol; 2023 Oct; 19(4):80. PubMed ID: 37719044
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with the development of extrahepatic malignancy in patients with nonalcoholic fatty liver disease: a single-center longitudinal study.
Gumussoy M; Koc O; Karatas G; Ozercan M; Ellik Z; Duman S; Kiremitci S; Gokcan H; Elhan AH; Savas B; Idilman R
Eur J Gastroenterol Hepatol; 2022 Nov; 34(11):1172-1177. PubMed ID: 36170687
[TBL] [Abstract][Full Text] [Related]
14. Progression to cirrhosis is similar among all ages in nonalcoholic fatty liver disease, but liver-related events increase with age.
Miller MJ; Harding-Theobald E; DiBattista JV; Zhao Z; Wijarnpreecha K; Lok AS; Chen VL
Hepatol Commun; 2023 Jun; 7(6):. PubMed ID: 37267221
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study.
Iwaki M; Fujii H; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T
Clin Mol Hepatol; 2024 Apr; 30(2):225-234. PubMed ID: 38263684
[TBL] [Abstract][Full Text] [Related]
16. Predictability of noninvasive liver fibrosis score for cardiac events in patients with nonalcoholic fatty liver disease.
Shibata N; Ito T; Toyoda H; Tanaka A; Morita Y; Kanzaki Y; Watanabe N; Yoshioka N; Yasuda S; Morishima I
Nutr Metab Cardiovasc Dis; 2024 Mar; ():. PubMed ID: 38664121
[TBL] [Abstract][Full Text] [Related]
17. Association between non-alcoholic fatty liver disease and cancer incidence rate.
Kim GA; Lee HC; Choe J; Kim MJ; Lee MJ; Chang HS; Bae IY; Kim HK; An J; Shim JH; Kim KM; Lim YS
J Hepatol; 2017 Nov; ():. PubMed ID: 29150142
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic faty liver disease and liver fibrosis score have an independent relationship with the presence of mitral annular calcification.
Ergül E; Emlek N; Yılmaz AS; Öztürk M; Aydın C; Durak H; Çetin M
Int J Cardiovasc Imaging; 2023 Aug; 39(8):1431-1436. PubMed ID: 37149841
[TBL] [Abstract][Full Text] [Related]
19. Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis.
Liu SS; Ma XF; Zhao J; Du SX; Zhang J; Dong MZ; Xin YN
Lipids Health Dis; 2020 May; 19(1):118. PubMed ID: 32475354
[TBL] [Abstract][Full Text] [Related]
20. Association between Major Adverse Cardiovascular Events and the Liver Fibrosis Score in Patients with and without Coronary Artery Disease: From the FU-CCTA Registry.
Ajimu Y; Shiga Y; Hirata T; Tashiro K; Higashi S; Kawahira Y; Suematsu Y; Kato Y; Kuwano T; Sugihara M; Miura SI
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
